Literature DB >> 9708182

Recombinant cholera toxin B subunit is not an effective mucosal adjuvant for oral immunization of mice against Helicobacter felis.

T G Blanchard1, N Lycke, S J Czinn, J G Nedrud.   

Abstract

Cholera toxin is a potent oral mucosal adjuvant for enteric immunization. Several studies suggest that commercial cholera toxin B subunit (cCTB; purified from holotoxin) may be an effective non-toxic alternative for oral immunization. The present study was performed, using an infectious disease model, to determine if the oral mucosal adjuvanticity of CTB is dependent on contaminating holotoxin. Mice were orally immunized with Helicobacter felis sonicate and either cholera holotoxin, cCTB or recombinant cholera toxin B subunit (rCTB). Serum immunoglobulin G (IgG) and intestinal immunoglobulin A (IgA) antibody responses were determined and the mice were challenged with live H. felis to determine the degree of protective immunity induced. All orally immunized mice responded with serum IgG antibody titres regardless of the adjuvant used. However, only mice immunized with either holotoxin or the cCTB responded with an intestinal mucosal IgA response. Consistent with the production of mucosal antibodies, mice immunized with either holotoxin or cCTB as adjuvants were protected from challenge while mice receiving H. felis sonicate and rCTB all became infected. cCTB induced the accumulation of cAMP in mouse thymocytes at a level equal to 0.1% of that induced by holotoxin, whereas rCTB was devoid of any activity. These results indicate that CTB possesses no intrinsic mucosal adjuvant activity when administered orally. Therefore, when used as an oral adjuvant, CTB should also include small, non-toxic doses of cholera toxin.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9708182      PMCID: PMC1364326          DOI: 10.1046/j.1365-2567.1998.00482.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  34 in total

1.  A simple radioimmunoassay for 3',5', cyclic adenosine monophosphate.

Authors:  R W Farmer; C A Harrington; D H Brown
Journal:  Anal Biochem       Date:  1975-04       Impact factor: 3.365

2.  Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit.

Authors:  S Tamura; Y Samegai; H Kurata; T Nagamine; C Aizawa; T Kurata
Journal:  Vaccine       Date:  1988-10       Impact factor: 3.641

3.  Recombinant system for overexpression of cholera toxin B subunit in Vibrio cholerae as a basis for vaccine development.

Authors:  J Sanchez; J Holmgren
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

4.  Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin.

Authors:  C O Elson; W Ealding
Journal:  J Immunol       Date:  1984-06       Impact factor: 5.422

5.  Cholera toxin B subunit as a carrier protein to stimulate a mucosal immune response.

Authors:  S J McKenzie; J F Halsey
Journal:  J Immunol       Date:  1984-10       Impact factor: 5.422

Review 6.  Actions of cholera toxin and the prevention and treatment of cholera.

Authors:  J Holmgren
Journal:  Nature       Date:  1981-07-30       Impact factor: 49.962

7.  Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens.

Authors:  N Lycke; J Holmgren
Journal:  Immunology       Date:  1986-10       Impact factor: 7.397

8.  Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis.

Authors:  C K Lee; R Weltzin; W D Thomas; H Kleanthous; T H Ermak; G Soman; J E Hill; S K Ackerman; T P Monath
Journal:  J Infect Dis       Date:  1995-07       Impact factor: 5.226

9.  Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant.

Authors:  A Di Tommaso; G Saletti; M Pizza; R Rappuoli; G Dougan; S Abrignani; G Douce; M T De Magistris
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

10.  Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin.

Authors:  K Hashigucci; H Ogawa; T Ishidate; R Yamashita; H Kamiya; K Watanabe; N Hattori; T Sato; Y Suzuki; T Nagamine; C Aizawa; S Tamura; T Kurata; A Oya
Journal:  Vaccine       Date:  1996-02       Impact factor: 3.641

View more
  16 in total

Review 1.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

2.  Induction of cell signaling events by the cholera toxin B subunit in antigen-presenting cells.

Authors:  Aletta C Schnitzler; Jennifer M Burke; Lee M Wetzler
Journal:  Infect Immun       Date:  2007-03-12       Impact factor: 3.441

3.  Comparison of serum humoral responses induced by oral immunization with the hepatitis B virus core antigen and the cholera toxin B subunit.

Authors:  Katleen Broos; Michiel E Janssens; Ine De Goeyse; Peter Vanlandschoot; Geert Leroux-Roels; Dirk Geysen; Yves Guisez
Journal:  Clin Vaccine Immunol       Date:  2008-03-26

Review 4.  Identification of Helicobacter pylori and the evolution of an efficacious childhood vaccine to protect against gastritis and peptic ulcer disease.

Authors:  Thomas G Blanchard; Steven J Czinn
Journal:  Pediatr Res       Date:  2016-10-04       Impact factor: 3.756

Review 5.  Emergence of diverse Helicobacter species in the pathogenesis of gastric and enterohepatic diseases.

Authors:  J V Solnick; D B Schauer
Journal:  Clin Microbiol Rev       Date:  2001-01       Impact factor: 26.132

6.  Comparison of memory B cell, antibody-secreting cell, and plasma antibody responses in young children, older children, and adults with infection caused by Vibrio cholerae O1 El Tor Ogawa in Bangladesh.

Authors:  Daniel T Leung; Mohammad Arif Rahman; M Mohasin; M Asrafuzzaman Riyadh; Sweta M Patel; Mohammad Murshid Alam; Fahima Chowdhury; Ashraful Islam Khan; Eric J Kalivoda; Amena Aktar; M Saruar Bhuiyan; Regina C LaRocque; Jason B Harris; Stephen B Calderwood; Firdausi Qadri; Edward T Ryan
Journal:  Clin Vaccine Immunol       Date:  2011-06-22

7.  Regulation of murine dendritic cell immune responses by Helicobacter felis antigen.

Authors:  Maureen L Drakes; Steven J Czinn; Thomas G Blanchard
Journal:  Infect Immun       Date:  2006-08       Impact factor: 3.441

8.  Oral immunisation of mice with transgenic rice calli expressing cholera toxin B subunit fused to consensus dengue cEDIII antigen induces antibodies to all four dengue serotypes.

Authors:  Mi-Young Kim; Byeong-Young Kim; Sun-Mi Oh; Rajko Reljic; Yong-Suk Jang; Moon-Sik Yang
Journal:  Plant Mol Biol       Date:  2016-08-26       Impact factor: 4.076

Review 9.  The ABC of clinical and experimental adjuvants--a brief overview.

Authors:  Richard Brunner; Erika Jensen-Jarolim; Isabella Pali-Schöll
Journal:  Immunol Lett       Date:  2009-11-04       Impact factor: 3.685

10.  Challenge model for Helicobacter pylori infection in human volunteers.

Authors:  D Y Graham; A R Opekun; M S Osato; H M T El-Zimaity; C K Lee; Y Yamaoka; W A Qureshi; M Cadoz; T P Monath
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.